Exelexis slashes workforce by 70%


US biotech firm Exelexis is cutting around 160 jobs (70% of its workforce). The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer (mCRPC).

The job cuts will leave behind just 70 employees, but the firm anticipates that the cost savings will leave it with ‘sufficient cash to support its operations through to the release of top-line results of [a trial of Cometriq in metastatic renal cell carcinoma] next year’.

A glance at Exelexis’ financial results reveals why such drastic cuts are needed. Cometriq is already approved in the US to treat metastatic medullary thyroid cancer, and brought in $6.5 million (£4 million) in revenue in the second quarter of 2014. However, the firm has made overall operating losses of over $55 million in each quarter of the last year, including spending $47–51 million on R&D. With only $87 million in working capital on its balance sheet, cutting staff and any peripheral clinical trial programmes allows the company to continue its most promising trials in the hope of positive results.


Related Content

Takeda slashes 10% of its workforce

20 January 2012 News Archive

news image

Japanese pharmaceutical firm sheds 2800 jobs in the US and Europe after recent takeover of Nycomed

Business roundup

23 February 2009 Business

news image

Industry news, March 2009

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint